Wynn Capital LLC Takes Position in Pfizer Inc. (NYSE:PFE)

Wynn Capital LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 21,423 shares of the biopharmaceutical company’s stock, valued at approximately $617,000.

Other large investors also recently made changes to their positions in the company. Wedge Capital Management L L P NC grew its holdings in Pfizer by 10.6% during the third quarter. Wedge Capital Management L L P NC now owns 10,865 shares of the biopharmaceutical company’s stock valued at $360,000 after purchasing an additional 1,044 shares during the period. Essex LLC increased its holdings in shares of Pfizer by 16.4% in the third quarter. Essex LLC now owns 66,014 shares of the biopharmaceutical company’s stock worth $2,190,000 after buying an additional 9,288 shares during the period. Capital Investment Advisors LLC grew its stake in shares of Pfizer by 5.9% in the third quarter. Capital Investment Advisors LLC now owns 718,558 shares of the biopharmaceutical company’s stock worth $23,835,000 after purchasing an additional 40,233 shares during the last quarter. Guidance Capital Inc. boosted its position in Pfizer by 9.9% during the 3rd quarter. Guidance Capital Inc. now owns 15,080 shares of the biopharmaceutical company’s stock valued at $511,000 after acquiring an additional 1,358 shares in the last quarter. Finally, Onyx Bridge Wealth Group LLC lifted its holdings in shares of Pfizer by 12.1% during the third quarter. Onyx Bridge Wealth Group LLC now owns 17,201 shares of the biopharmaceutical company’s stock valued at $571,000 after purchasing an additional 1,852 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Finally, Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $36.33.

Pfizer Stock Performance

Shares of PFE traded down $0.06 during mid-day trading on Wednesday, hitting $26.26. The company’s stock had a trading volume of 24,501,011 shares, compared to its average volume of 41,887,898. The firm has a market capitalization of $148.70 billion, a PE ratio of 72.97, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. Pfizer Inc. has a one year low of $25.23 and a one year high of $40.37. The stock’s 50-day moving average is $27.07 and its two-hundred day moving average is $28.52. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same period last year, the company posted $1.14 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.40%. Pfizer’s payout ratio is 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.